Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients

Transplant Immunology

Volumn 23, Issue 4, 2010, Pages 166-169

  Sun, Hsin Yun ^a,b   Cacciarelli, Thomas V ^b,c   Wagener, Marilyn M ^c   Singh, Nina ^b,c  

^a VA Pittsburgh Healthcare System   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cytomegalovirus; Liver transplant; Preemptive therapy; Real time polymerase chain reaction

Indexed keywords

VALGANCICLOVIR;

ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; MYCOSIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; VIREMIA; VIRUS LOAD;

ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; MONITORING, PHYSIOLOGIC; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77956061354     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.06.013     Document Type: Article

References (31)

1. Kanj S.S., Sharara A.I., Clavien P.A., Hamilton J.D. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996, 22:537-549.
2. Amorim M.L., Cabeda J.M., Seca R., Mendes A.C., Castro A.P., Amorim J.M. CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays. BMC Infect Dis 2001, 1:2.
3. Boeckh M., Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11:533-554.
4. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp 65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind trial. Blood 1996, 88:4063-4071.
5. Diaz-Pedroche C., Lumbreras C., San Juan R., Folgueira D., Andrs A., Delgado J., et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006, 82:30-35.
6. Sagedall S., Nordal K.P., Haartmann A., Midtvedt K., Foss A., Asberg A., et al. Pre-emptive therapy of CMV pp 65 antigen positive renal transplant recipients with oral ganciclovir; a randomized, comparative study. Nephrol Dial Transplant 2003, 18:1899-1908.
7. Singh N., Paterson D.L., Gayowski T., Wagener M.M., Marino I.R. Cyomegalovirus antigenemia directed preemptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus diseases in liver transplant recipients: a randomized, controlled trial. Transplantation 2000, 70:717-2.
8. Gimeno C., Solano C., Latorre J.C., Hernandez-Boluda J.C., Clari M.A., Remigia M.J., et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008, 46:3311-3318.
9. Lilleri D., Germna G., Furione M., Bernardo M.E., Giorgiani G., Telli S., et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoitic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood 2007, 110:2757-2760.
10. Kim D.J., Kim S.J., Park J., Choi G.S., Lee S., Kwon C.D., et al. Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients. Transplant Proc 2007, 39:1458-1460.
11. Sanghavi S.K., Abu-Elmagd K., Keightley M.C., St George K., Lewandowski K., Boes S.S., et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp 65 antigenemia in organ transplant recipients. J Clin Virol 2008, 42:335-342.
12. Choi S.M., Lee D.G., Lim J., Park S.H., Choi J.H., Yoo J.H., et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp 65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci 2009, 24:571-578.
13. Kanda Y., Yamashita T., Mori T., Ito T., Tajika K., Mori S., et al. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant 2009, doi:10.1038/bmt.2009.337.
14. Reischig T., Jindra P., Hes O., Bouda M., Kormunda S., Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009, 87:436-444.
15. Franco A., Serrano R., Gimeno A., de Juan J., Merino E., Jimenez del Cerro L., et al. Study on the viral load and antigenemaia as predictive values of CMV infection relapse in renal transplantation. Nefrologia 2007, 27:202-208.
16. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
17. Sun H.Y., Cacciarelli T.V., Singh N. Impact of pretransplant infections on clinical outcomes of liver transplant recipients. Liver Transpl 2010, 16:222-228.
18. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections. Am J Infect Control 1988, 16:128-140.
19. Benmarzouk-Hidalgo O.J., Cordero E., Martin-Pena A., Garcia-Prado E., Gentil M.A., Gomez-Bravo M.A., et al. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antivir Ther 2009, 14:641-647.
20. Humar A., Gregson D., Caliendo A.M., McGeer A., Malkan G., Krajden M., et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999, 68:1306-1311.
21. Hassan-Walker A.F., Kidd I.M., Sabin C., Sweny P., Griffiths P.D., Emery V.C. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antihymocyte globulin (ATG). J Med Virol 1999, 58:182-187.
22. Hernando S., Folgueira L., Lumbreras C., San Juan R., Maldonado S., Prieto C., et al. Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplant Proc 2005, 37:4094-4096.
23. Singh N., Gayowski T., Wagener M.M., Cacciarelli T. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset CMV disease. Transplantation 2005, 79:85-90.
24. Gerna G., Zavattoni M., Percivalle E., Grossi P., Torsellini M., Grazia-Revello M. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection. J Clin Microbiol 1998, 36:1113-1116.
25. Mattes F.M., Hainsworth E.G., Hassan-Walker A.F., Burroughs A.K., Sweny P., Griffiths P.D., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005, 191:89-92.
26. Tormo N., Solano C., Benet I., Clari M.A., Nieto J., de la Camara R., et al. Lack of prompt expansion of cytomegalovirus pp 65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2010, 45:543-549.
27. Sun H.Y., Wagener M.M., Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008, 8:2111-2118.
28. Humar A., Lebranchu Y., Vincenti F., Blumberg E.A., Punch J.D., Limaye A.P., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10(5):1228-1237.
29. Helantera I, Kyllonen L, Lautenschlager I, Salmela K, Koskinen P. Primary CMV infections are common in kidney transplant recipients after 6months valganciclovir prophylaxis. American Transplant Congress. San Diego CA2010.
30. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001, 11:83-86.
31. Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. Clin Infect Dis 2008, 47:296-297. Author reply 7.